28 KDA GST PROTEINS FROM SCHISTOSOMA FOR THE USE THEREOF IN THE TREATMENT OF INFLAMMATORY AUTOIMMUNE DISEASES GENERATING A TH1 AND/OR TH17 RESPONSE

摘要

The present invention relates to a product selected from a protein, a fragment of the protein, a derived sequence and a homologous sequence of the protein, the protein including or being constituted by the 28 kDa glutathione S-transferase protein from a schistosome selected from Schistosoma haematobium, Schistosoma mansoni, Schistosoma bovis represented respectively by the sequences SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 for the use thereof in the treatment of an inflammatory autoimmune disease generating a response of type Th1 and/or Th17.

主权项

1. Product selected from a protein, a fragment of said protein, a derived sequence and a homologous sequence of said protein, characterized in that:
said protein comprises or is constituted by the 28 kDa glutathione S-transferase protein from a schistosome selected from Schistosoma haematobium, Schistosoma mansoni, Schistosoma bovis represented by the sequences SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, respectively; said fragment is a fragment of one of said proteins provided that it induces a type-Th2 immune response and/or decreases the Th1-type response, said fragment comprising at least one region from among the following regions: the region comprised from the amino acid in position 15 to the amino acid in position 60, the region comprised from the amino acid in position 20 to the amino acid in position 50, the region comprised from the amino acid in position 24 to the amino acid in position 43, the region comprised from the amino acid in position 170 to the amino acid in position 220, in particular the region comprised from the amino acid in position 180 to the amino acid in position 215, preferably the region comprised from the amino acid in position 190 to the amino acid in position 211 of the sequence SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; said derived sequence is derived from one of said sequences SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 or from one of said aforementioned fragments and in particular is obtained by suppression, substitution or addition of one or more amino acids, in the sequence SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3, said derived sequence comprising at least one region from among the following regions: the region comprised from the amino acid in position 15 to the amino acid in position 60, the region comprised from the amino acid in position 20 to the amino acid in position 50, the region comprised from the amino acid in position 24 to the amino acid in position 43, the region comprised from the amino acid in position 170 to the amino acid in position 220, the region comprised from the amino acid in position 180 to the amino acid in position 215 and the region comprised from the amino acid in position 190 to the amino acid in position 211 of the sequence SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; thereby leading to the induction of a Th2 response and/or the decrease of the Th1 response; and said homologous sequence is a homologous sequence of one of said sequences SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 or of one of said fragments, and has an identity of at least 80% and in particular of at least 85% with at least one of the following regions of said sequences: the region comprised from the amino acid in position 15 to the amino acid in position 60, the region comprised from the amino acid in position 20 to the amino acid in position 50, the region comprised from the amino acid in position 24 to the amino acid in position 43, the region comprised from the amino acid in position 170 to the amino acid in position 220, the region comprised from the amino acid in position 180 to the amino acid in position 215, and the region comprised from the amino acid in position 190 to the amino acid in position 211 of the sequence SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; or with the whole of one of the sequences SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; thereby leading to the induction of a Th2 response and/or the decrease of the Th1 response, for the use thereof in the preventive and/or therapeutic treatment of a chronic inflammatory disease connected with an immune system disorder generating an immune response of type Th1/Th17.